Table 1.
Pretreatment characteristics of patients and tumors
| Parameter | Total n = 66 |
CF group n = 47 |
DCF group n = 19 |
P-value | |
|---|---|---|---|---|---|
| Age (years) | ≥ 65 | 39 | 30 (76.9%) | 9 (23.1%) | 0.273 |
| < 65 | 27 | 17 (63.0) | 10 (37.0) | ||
| Sex | Male | 51 | 38 (74.5) | 13 (25.5) | 0.335 |
| Female | 15 | 9 (60.0) | 6 (40.0) | ||
| Tumor location | Upper/middle | 46 | 33 (71.7) | 13 (28.3) | 1.000 |
| Lower/abdominal | 20 | 14 (70.0) | 6 (30.0) | ||
| Histological type | Well/moderate | 54 | 37 (68.5) | 17 (31.5) | 0.484 |
| Poor/basaloid | 12 | 10 (83.3) | 2 (16.7) | ||
| Clinical T factor | cT1/cT2 | 22 | 20 (90.9) | 2 (9.1) | 0.019* |
| cT3/cT4 | 44 | 27 (61.4) | 17 (38.6) | ||
| Clinical N factor | cN0 | 17 | 14 (82.4) | 3 (17.6) | 0.354 |
| cN1–cN4 | 49 | 33 (67.3) | 16 (32.7) | ||
| Clinical stage | II | 18 | 18 (100) | 0 (0) | < 0.001* |
| III/IVa | 48 | 29 (60.4) | 19 (39.6) |
CF cisplatin/5-fluorouracil, DCF docetaxel/cisplatin/5-fluorouracil
*Statistically significant